A review addresses a specific and recognisable failure: a mesenchymal tumour with prominent inflammation arrives on the bench, the inflammation dominates the field, and soft tissue entities are never entered into the differential at all. The lesions covered are those the authors identify as commonly encountered or prone to recurrent pitfalls — inflammatory well-differentiated liposarcoma and atypical lipomatous tumour, angiomatoid fibrous histiocytoma, myxoinflammatory fibroblastic sarcoma, inflammatory myofibroblastic tumour, mass-forming fibroinflammatory lesions, and vascular tumours with associated inflammation.
The structural point is that the error is one of framing rather than of morphological skill. Each of these has described features and available ancillary studies, and none of them is subtle once considered; the diagnosis fails at the stage of deciding what kind of lesion this might be. A prominent inflammatory infiltrate in a mass reads as reactive because reactive processes are far commoner, and that base rate is what does the damage.
The review's own framing of the remedy is threefold: morphological features, the clinical presentation, and appropriate ancillary studies together — not any one of them alone. Clinical presentation carries more weight here than usual, because a mass lesion presenting as a mass is the fact most likely to be missing from the requesting form and most likely to redirect the differential.
In a laboratory without immediate access to fusion testing or a soft tissue reference opinion, the practical version is a threshold for deferring: an inflamed lesion described clinically as a discrete mass, particularly deep or retroperitoneal, warrants the soft tissue differential being written into the report and the case being shown to someone else before a reactive diagnosis is issued.
- Enter the soft tissue differential explicitly for any inflamed lesion presenting clinically as a discrete mass
- Ask for the clinical presentation before signing out an inflamed mesenchymal lesion — a mass forming lesion changes the differential
- Treat a deep or retroperitoneal inflamed lesion as needing the malignant differential excluded rather than the reactive one confirmed
- Use ancillary studies directed at the specific entities in the differential rather than a broad panel
- Defer or seek a second opinion before issuing a reactive diagnosis on a mass-forming inflamed lesion
Why it matters
The diagnosis is missed at the point of framing the differential, not at the microscope, which is why morphological skill does not protect against it.
Don't overread it
This is a narrative review of diagnostic pitfalls, not a study of how often the error occurs or of what reduces it.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for pathology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free